Monograph Details
|
|
Ob/Gyn
> Contraception
|
|
DEPO-PROVERA |
| Manufacturer |
|
Pfizer Labs |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Progestin. |
| Generic Name |
|
Medroxyprogesterone acetate 150mg/mL; IM inj. |
| Also |
|
• DEPO-SUBQ PROVERA
|
| Indications |
|
Injectable contraception. |
| Children |
|
Not applicable. |
| Adults |
|
150mg IM every 3 months. Give 1st dose within 5 days of onset of normal menses. Do not use for >2 years unless other methods are inadequate. |
| Contraindications |
|
Undiagnosed vaginal bleeding. Breast carcinoma. Cerebrovascular disease. Hepatic dysfunction. Pregnancy (Cat.X). |
| Precautions |
|
Conditions aggravated by fluid retention (eg, migraine). Depression. Pretreatment exam should include Pap smear. Risk of osteoporosis (eg, metabolic bone disease, anorexia, family history). Discontinue if jaundice, visual disturbances, migraine or thrombotic disorders occur. Nursing mothers. |
| Interactions |
|
May be antagonized by aminoglutethimide. May reduce bone mass with anticonvulsants, corticosteroids; avoid alcohol, tobacco. |
| Adverse Reactions |
|
Irregular bleeding, edema, weight or cervical changes, decreased bone mineral density, cholestatic jaundice, depression, breast tenderness, acne, hirsutism, inj site reactions. |
| How Supplied |
Vials—1, 25
Prefilled syringes (1mL)—1, 6, 24
SubQ (prefilled syringe)—1 (w. needle) |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
